Talaris Therapeutics, Inc. Funds Closed $115 Million

November 2, 2020

Talaris Therapeutics, Inc. is under the spotlight for raising funds. It isn’t the first time a company has received so much attention on news like so. Funds are filed for and received for numerous reasons, especially by biotechnological companies.

If you’re curious to find out more about the cause behind the funding, it’s worth reading till the end.

Financing Details

The $115 million funding is a Series B financing. While this was closed, Phase 3 registration trials were going on. Talaris is conducting these trials for its main product. It’s for supporting living donor kidney transplants. Besides, the company has scheduled the Phase 2 trial for next year.

Interestingly, numerous companies such as Tend are securing Series B financing. This act is also proving to be a useful ste...

Forgot Password
Notify of
Gulfport Energy Files for Chapter 11 Bankruptcy with $2.5 Billion in Debt

Bankruptcy Angelina Vasilevsky
Gulfport Energy Corporation, which owns and operates oil and gas properties within the Louisiana Gulf Coast, filed for Chapter 11 bankruptcy in...

The Recent Evolution of Biotechnology

Articles Diana Rangaves, PharmD
There is no doubt we’re observing immense progress in the macroscopic biomedical biotechnology sciences. Analyzing living cells and tissues is more practical than ever yet.